The Quest for NCI DesignationA report on our accomplishments

e University of Kansas Cancer Center submitsits application for National Cancer Institute (NCI)designation in September 2011. e applicationis possible only through unprecedented supportfrom individuals, businesses and communitiesthroughout the region.[

3

Backgrounde University of Kansas Medical Center (KUMC) has been working to eliminate the burden of cancer for decades. Its cancer program was started in 1969, with itsfirst American Cancer Society Professor of Clinical Oncology and support from theKansas Masonic Foundation. In the early 1970s, the National Cancer Institute (NCI)awarded KUMC funding to investigate the feasibility of establishing a clinical cancerresearch center in Kansas. By the 1990s, the cancer center was experiencing steadygrowth in research funding and discoveries.

Since 2002, it has been KUMC’s goal to achieve NCI Cancer Center designation, the gold standard for cancer institutes across the country. NCI-designated CancerCenters are recognized for their scientific excellence and are awarded federal fundingthrough a rigorous peer review process. ey are a major source of discovery anddevelopment of more effective approaches to cancer prevention, diagnosis andtreatment. NCI Cancer Centers also educate health care professionals and delivermedical advances to patients and their families.

In 2004, KUMC renamed its cancer research organization the Kansas MasonicCancer Research Institute, reflecting a commitment of $20 million by the KansasMasonic Foundation to support cancer research on the KUMC campus. e giftallowed KUMC to recruit the cancer center’s first full-time director, Roy A. Jensen,MD, a nationally recognized breast cancer researcher and pathologist from the NCI-designated Vanderbilt-Ingram Cancer Center.

In 2005, attaining NCI designation was named KU's top research priority. Since then,e University of Kansas Cancer Center has become a leader in research and patientcare, while generating significant economic development. is report focuses onhighlights in the quest to attain NCI designation.

2006• e Kansas Legislature approves a $5 million

appropriation for the cancer center beginning infiscal year 2007. e legislature has continued thisappropriation each year.

• e cancer center establishes the Drug Discovery,Delivery & Experimental erapeutic program(D3ET). D3ET leverages world-class cancer biologyresearch at KU, KUMC and the Stowers Institute for Medical Research with the strengths of themedicinal and pharmaceutical chemistry research atthe nationally ranked KU School of Pharmacy. ScottWeir, PharmD, PhD, a 25-year veteran of companiessuch as Marion Laboratories, Hoechst MarionRoussel and Aventis Pharmaceuticals, arrives tolead the program.

• D3ET program leader Valentino Stella, PhD, a professor of medicinal chemistry at KU, has a longstanding contract with NCI to conductresearch on promising drug therapies. Under Dr. Stella’s contract, eight of the 17 NCI cancerdrug therapies advancing to clinical trials havebeen formulated at KU.

• e American Cancer Society and the AmericanLung Association award KUMC $1.2 million torecruit American Indian smokers and examine the effectiveness of culturally sensitive smoking-cessation programs that respect tobacco’s role inAmerican Indian traditions.

2007• KUMC launches the Midwest Cancer Alliance,

a regional network of health care and researchorganizations focused on enhancing researchcollaborations and increasing access to clinical trials and other cancer care resources. By 2011,members include Children’s Mercy Hospitals andClinics, Kansas Bioscience Authority, Kansas StateUniversity, Stowers Institute for Medical Research,Stormont-Vail HealthCare, Truman Medical Centers,e University of Kansas Hospital, GoodlandRegional Medical Center, Hays Medical Center,Promise Regional Medical Center in Hutchinson,Salina Regional Health Center, St. Francis HealthCenter, Saint Luke’s Health System, and Via ChristiHospital in Pittsburg.

“I returned toKansas to be a part of a verybig dream: tocreate a trulyworld-class cancer center. I do not intendto rest until thatdream becomesa reality.”

Roy A. Jensen, MDDirector, e University of

Kansas Cancer Center

4

5

• Kansas Sen. Barbara Allen (R-Overland Park), a breast cancer survivor, leads efforts to passlegislation creating a “Driven to Cure” licenseplate. For every plate sold, $50 is contributed to e University of Kansas Cancer Center forresearch and outreach.

• e University of Kansas Hospital and the Kansas City Cancer Center combine blood andmarrow transplant services. is establishes the area’s largest blood and marrow transplant(BMT) program, providing lifesaving treatmentsfor patients with leukemia, lymphoma, multiplemyeloma and other related blood diseases.

• e University of Kansas Hospital’s outpatientCancer Center and Medical Pavilion, the largestoutpatient center in the region, opens at the formerSprint headquarters in Westwood. Designed todeliver advanced medical care and the best patientexperiences, the 55,000-square-foot facility is aresponse to significant patient volume growth. Newcancer case volume has grown 75 percent since 2001to more than 1,800 new cancer patients in 2007.

• After touring the new outpatient Cancer Center and Medical Pavilion,philanthropist and civic leader AnnetteBloch announces a $1 million gift tosupport patient care.

• With a gift from Back in the Swing, a Kansas City-based not-for-profit organization, the BreastCancer Survivorship Center opens in theWestwood facility. It is the region’s first such center,incorporating clinical, research and psychosocialprograms to serve the needs of breast cancersurvivors and provide a model that can beexpanded to other cancer types.

2008• e NCI invites KU to apply for cancer center

designation on September 25, 2011.

• e University of Kansas Hospital’s cancer programis awarded the Commission on Cancer OutstandingAchievement Award from the American College of Surgeons for the second consecutive time. eaward is among the most prestigious for cancercenters, with only about 15 percent of 1,345 cancerprograms surveyed in 2007 receiving the award.

• e University of Kansas Cancer Center opens aPhase I clinical trial using a new ovarian cancerdrug developed by KU researchers. e drug,Nanotax, is the reformulation of a commonly usedchemotherapy drug, Paclitaxel. Negative side effectsassociated with Paclitaxel are attributed to thesolvent that it is mixed with in order to beadministered to patients. KU researchers believeNanotax will be a less-toxic, more effectivetreatment.

• At the urging of e University of Kansas CancerCenter and other advocacy organizations, statepolicymakers remove barriers for cancer patientsin clinical trials, preserving insurance coverage forroutine medical services.

• In what is believed to be the largest individual gift ever made to a hospital in the Kansas City area or the state of Kansas, Annette Bloch donates $20 million to e University of Kansas Hospitalcancer services. e hospital renames its Westwoodoutpatient cancer facility the Richard and AnnetteBloch Cancer Care Pavilion. e Blochs' names also appear on the radiation oncology building on KU Medical Center’s main campus.

• Cheryl Jernigan, chair of the Advancement Boardfor KU Medical Center, e University of KansasHospital and e University of Kansas Physicians, is selected to join the NCI Director’s ConsumerLiaison Group. Jernigan is one of four new memberschosen from 75 applicants. Her role is to advise theNCI from a cancer patient’s perspective.

• Voters in Johnson County, Kan., pass a 1/8-centsales tax for the Johnson County Education andResearch Triangle (JCERT). Revenue will help fundthe KU Clinical Research Center, site of early phaseclinical trials for cancer and other new therapies.

• e cancer center establishes the Midwest CancerAlliance Partners Advisory Board, a group of CEOsfrom health care and research organizations. eboard serves in an advisory role to the cancer centerdirector and works to move the NCI designationeffort forward.

Annette Bloch

7

2009• e Institute for Advancing Medical Innovation

(IAMI) is formed with an $8.1 million grant from the Kauffman Foundation, matched by KU Endowment. Led by Dr. Weir, who is also theleader of the cancer center’s D3ET program, IAMI’smission is to streamline the development anddelivery of drugs and biomedical devices.

• KU and Kansas State University meet in thegovernor’s office to sign a Memorandum ofUnderstanding formalizing their commitment tocollaborate on working toward NCI designation.

• e Kansas Bioscience Authority (KBA) awards more than $29 million for state-of-the-art cancerresearch space and to recruit cancer-related EminentScholars (researchers who are nationally recog nizedfor their scientific achievements and entrepreneurialspirits to enhance innovative research that leads to economic gains) and Rising Star Scholars (world-class bioscience scholars with proven records ofgrant productivity, team leadership in a researchenvironment and an interest in applying research to commercial opportun ities to build Kansas’bioscience economy). In part, the KBA investmentwill support 10 years of bond payments forconstruction to renovate the Wahl/Hixon ResearchComplex, estimated to cost $53 million.

• Construction begins on the Wahl/Hixon ResearchComplex, renovating 170,000 square feet on theKU Medical Center campus to house 37 cancer-focused researchers.

• e Leukemia & Lymphoma Society names e University of Kansas Cancer Center a nationalacademic partner through the erapy AccelerationProgram (TAP). TAP supports private-sector andacademic-based projects to move blood cancertreatments into the develop ment pipeline andcloser to commercialization.

• KU orthopedic surgeons are the first in the countryto perform targeted muscle reinnervation on acancer patient.

• After two years of extraordinary growth in its blood and marrow transplant program, e University of Kansas Hospital opens a 7,500-square-foot facility for the BMT program at theRichard and Annette Bloch Cancer Care Pavilion inWestwood. e program has grown by 92 percentfrom 2006 to 2007 and another 53 percent in 2008.

• KU Endowment and e University of Kansas CancerCenter announce a fundraising initiative to supportthe NCI-designation effort. e AdvancementBoard, formed in 2005 to develop community andpolitical support and to bolster fundraising effortsfor education, research and patient care at theacademic medical center, launches the CancerFunding Partners. is volunteer-led effort to fostercivic, business and community support begins witha $1 million gift from the Sunderland Foundation.

• Urology Times, a leading medical magazine and themost widely circulated publication among urologistsnationwide, names the prostate cancer program ate University of Kansas Cancer Center one of 13“Clinical Centers of Excellence” in the country. It isthe only prostate cancer program in the state ofKansas or the Kansas City metropolitan area toreceive the honor.

• e Breast Center is selected as one of just 12 sites nationally for a major clinical research studysponsored by U-Systems, Inc., the developer of a 3D ultra sound breast imaging system, to determinewhether 3D automated breast ultrasound, combinedwith routine screening mammo graphy, is moreaccurate in detecting breast cancer in women withdense breast tissue than the routine screeningmammogram alone.

• KU Endowment announces that a $10 million gift from Joe and Jean Brandmeyer will create anendowed chair of Radiation Oncology and supportpatient care and research priorities needed toachieve NCI designation. e cancer center recruitsParvesh Kumar, MD, who is inter nationally knownfor his work in lung cancer, head and neck tumorsand prostate cancer, from the University ofSouthern California’s Keck School of Medicine toserve as the Joe and Jean Brandmeyer Chair andProfessor of Radiation Oncology.

8

2010• e Hall Family Foundation of Kansas City

commits $18 million to help recruit world-classscientists and fund a Phase I clinical trials facility inFairway. e foundation purchased the facility in2008 and is donating it to the cancer center. efoundation’s gift brings total private contributionsfor NCI designation to $37 million.

• After only 13 months, a team of researchers at e University of Kansas Cancer Center, theOntario Cancer Institute, the Leukemia &Lymphoma Society and Beckloff Associates advancea promising new therapy for leukemia into a PhaseI clinical trial. e researchers have discovered thatan antifungal cream could be reformulated to disruptmolecules in the body that are significant in thegrowth of leukemia.

• Supported by a $1 million donation from the Burns& McDonnell Foundation, the Prostate CancerHigh-Risk Prevention Program opens. It will help

high-risk patients focus on ways to decrease theirrisk of developing cancer and help patients whohave had prostate cancer learn ways to decreasetheir risk of recurrence.

• e cancer center joins the Friends of CancerResearch, the Kauffman Foundation, the KansasBioscience Authority and the Council for AmericanMedical Innovation to host a national town hallmeeting on the new role of academia in drugdevelopment and discovery. More than 200thought leaders from industry, academia, govern ment and philanthropic organizationsattend. Health and Human Services SecretaryKathleen Sebelius gives the keynote speech, and National Institutes of Health Director Francis Collins, MD, PhD, and Food and DrugAdministration Commissioner Margaret Hamburg,MD, lead a panel on how to speed drugs from benchto bedside. KU’s model is among the examples ofhow this process can be accelerated.

As an acad center, we renowned educators all of who toward the eliminatin

9

• Shrikant Anant, PhD, a pioneering biologist with a national reputation in gastrointestinal cancerresearch, renowned for discovering a gene thatcauses normal cells to turn into cancer cells, arrivesfrom the University of Oklahoma Cancer Instituteto become Associate Director of Cancer Preventionand Control. He is a KBA Eminent Scholar.

• Kapil Bhalla, MD, an internationally recognizedleader and physician scientist in the field of cancerbiology and targeted drug therapy, is recruited fromthe Medical College of Georgia Cancer Center toserve as Deputy Director at e University ofKansas Cancer Center. He is a KBA EminentScholar.

• Susan G. Komen for the Cure awards a $4.5 millionPromise Grant to Carol Fabian, MD, a leader inbreast cancer prevention research, to investigatewhether an estrogen found in flax seed – acommonly used supplement – can reduce the risk for breast cancer.

• e NIH awards KU researchers $12 million toimprove prevention and the chances of survivingcancer for rural, Latino and American Indiancommunities in Kansas. In the scientific community,these awards are known as the prestigious “U54” (a grant encompassing biological, biomedical,behavioral, social science, demographic and/orepidemiological research) and “P20” (for institutionswith relatively new research programs).

• Success rates soar for blood and marrow transplantpatients as the BMT program performs 179transplants, eclipsing the prior year’s record of 164. e program is also designated to serve as a National Marrow Donor Program-approvedcollection center. It is the only program in Kansaswith this distinction, which belongs to just 96 centers nationwide.

• Andrew K. Godwin, PhD, an internationallyrecognized leader in the field of translationalresearch and personalized medicine, arrives fromFox Chase Cancer Center in Philadelphia – one of the country’s first NCI-designated centers – to serve as Associate Director of TranslationalResearch. He is a KBA Eminent Scholar – and anative of Lawrence, Kan.

• Clinical programs extend care to 2,197 new cancerpatients and place 296 patients on therapeuticclinical trials, representing more than 13 percent of these new patients – exceeding the 10 percentbenchmark expectation for NCI-designated centers.

• Patients make more than 88,000 visits to theRichard and Annette Bloch Cancer Care Pavilion in Westwood this fiscal year.

• Missys’ Boutique opens in the Richard and AnnetteBloch Cancer Care Pavilion, providing a salon areafor wig fitting, a private room for fitting prosthesesand mastectomy garments and an array of jewelry,scarves, hats, skin-care products and gifts. It isnamed in memory of Melissa Malter Newell andAnn Wilcox O’Neill (both known as Missy), twowomen who lost battles with breast cancer aftereliciting promises from family members to helpother cancer patients. e boutique is fundedentirely through charitable contributions fromcorporations and individuals, including staff at e University of Kansas Hospital.

demic medical e bring together

researchers, and clinicians,

m work together e unified goal ofng cancer.

10

2011• e University of Kansas Cancer Center and the

Kansas City Cancer Center merge to create thearea’s premier outpatient cancer care organization,with more than 50 medical and radiation oncologistsworking in 12 locations throughout the metropolitanarea and a combined total of 216 therapeutic clinicaltrials.

• Danny Welch, PhD, a leading expert on tumorprogression, arrives from the University of Alabamaat Birmingham, where he was director of theNational Foundation for Cancer Research Centerfor Cancer Metastasis Research. He will serve as thecancer center’s Associate Director of Basic Science.He is a KBA Eminent Scholar.

• e University of Kansas Cancer Center’s firstpatient outcomes report documents excellentpatient survival rates. Actual survival rates at thecancer center exceed the average expected survivalrates. Breast cancer, lung cancer and renal cancermeet or exceed the combined rates of other leadingacademic centers in the country.

• e cancer center joins with the NIH and the Leukemia & Lymphoma Society to form e Learning Collaborative, an effort to discoverand develop new drug therapies for rare bloodcancers. Among their projects is Auranofin, whichrepurposes an arthritis drug used to treat chroniclymphocytic leukemia and is now in a clinical trialat Ohio State University, the National Heart, Lung and Blood Institute and KU. e LearningCollaborative establishes a cooperative research and development agreement (CRADA), giving KU and LLS the responsibility to further advancethe Auranofin project. e CRADA is the firstagreement executed between the NIH and non-profit partners.

• Raymond Perez, MD, an expert in early phaseclinical trials, arrives from Dartmouth’s NCI-designated Norris Cotton Cancer Center to directe University of Kansas Cancer Center’s Phase Iclinical trials program. He is a KBA Rising Star.

• KU Endowment announces that, thanks to thegenerosity of hundreds of donors, the $61 millionneeded to fund the cancer center’s NCI prioritieshas been raised ahead of the September 25application deadline.

• e KBA has committed more than $50 million tothe NCI designation effort, allowing the universityto invest in basic research, clinical trials, technology,faculty recruitment and major construction of state-of-the-art laboratories. KU has matched each KBAdollar, bringing the combined total to more than$100 million.

• e University of Kansas Hospital’s cancer programis named one of the nation’s best in U.S. News &World Report’s Best Hospitals 2011-12. Rankingsare based on measurable achievements in quality,patient safety, nursing excellence and other bestpatient care indicators.

• e KU Center for Telemedicine and Telehealth, thelongest-running program of its kind in the UnitedStates, has provided more than 2,196 teleoncologyconsults since 2006. is televideo technology also provides educational opportunities for healthprofessionals to learn about the latest technologies,treatments and services.

• e Midwest Cancer Alliance has collaborated withmember hospitals to hold community events acrossthe state. More than 10,000 individuals have beenscreened for cancer or received educational tools.

• e University of Kansas Cancer Center receivesspecial commendation from the American Collegeof Surgeons Commission on Cancer, a nationalaccrediting body. Fewer than half of organizationsthat apply receive full accreditation. is is thecancer center’s third consecutive three-yearaccreditation.

• Since its inception in January 2009, the Institute for Advancing Medical Innovation (IAMI) hascollaborated with industry, academia, governmentand disease philanthropy organizations to advanceseven new cancer drug therapies to clinical trials.

11

September 2011Kansas City’s four highly competitive television network affiliatesjoin together to simulcast a special, locally produced program, Be Part of the Cure™, to support e University of Kansas CancerCenter’s drive for NCI designation.

e University of Kansas Cancer Center submits its application for NCI designation.

Approximately 1,800 employees, including faculty, researchsupport, clinical and administrative staff, are specifically devoted to cancer care and research activities. We estimate that since 2006,the NCI designation pursuit has created 1,123 jobs and had aregional economic impact of $453 million.

e University of Kansas Clinical Research Center, a 77,000-square-foot facility funded through the Hall Family Foundation of KansasCity and the JCERT tax, will open in Fairway in early 2012. Patientsin the region will have greatly expanded access to promising Phase Iclinical trials.

Peer reviewers from the NCI will visit our site on February 22, 2012.We expect to learn whether we have been awarded NCI designationby early summer 2012.

Barbara Atkinson, MD, Executive Vice Chancellor,KUMC, and Executive Dean,KU School of Medicine

Bob Page, Presidentand CEO, e University of Kansas Hospital

Working Toward a World Without Cancer.®

Kansas Masonic Cancer Research Institute4030 Robinson Hall3901 Rainbow BoulevardKansas City, KS 66160

Richard and Annette Bloch Cancer Care Pavilion2330 Shawnee Mission ParkwayWestwood, KS 66205

913.588.1227kucancercenter.org